Genetix Touts Profitability, Plans Major Gene Therapy Expansion

SOMERVILLE, MA – March 02, 2026 – Fresh off a major corporate rebranding and its first-ever profitable quarter, Genetix Biotherapeutics today announced ambitious plans to double its manufacturing capacity and pursue full-year profitability in 2026. The privately-held company, a key player in the high-stakes field of genetic therapies for rare blood disorders, aims to build on a successful 2025 that saw a dramatic increase in patient demand for its one-time treatments, LYFGENIA™ for sickle cell disease and ZYNTEGLO™ for beta-thalassemia.

“2025 was a groundbreaking year for our Company on many fronts. New leadership rebranded the Company to Genetix Biotherapeutics, delivered strong revenue growth, increased patient demand, and achieved its first ever profitable quarter,” said David Meek, CEO of Genetix, in a statement. The company is now focused on scaling its operations to reach what it describes as "tens of thousands of untreated patients who could benefit from a one-time treatment."

A Swift Financial Turnaround

The announcement marks a significant turnaround for the business, which operated as the publicly traded bluebird bio before being taken private in a June 2025 acquisition by SK Capital Partners and The Carlyle Group. As bluebird bio, the company posted significant losses, including a net loss of over $240 million in 2024, highlighting the immense financial pressures of developing and commercializing cell and gene therapies.

The shift to private ownership and a new identity as Genetix Biotherapeutics was intended to sharpen the company's focus on commercial execution. The 2025 results suggest the strategy is bearing fruit. The company reported that over 100 patients received infusions last year, with more than 40 of those occurring in the final quarter. It also noted that 150 new patients completed their initial cell collection, a critical first step in the treatment process.

A key leading indicator of future growth, according to the company, was the enrollment of 150 new sickle cell disease patients for LYFGENIA treatment, a figure representing a nearly 100% increase from the prior year. This surge in demand underpins the company's aggressive 2026 forecast for "significant commercial growth and the Company’s first full year of profitability."

Scaling the Cure Amidst Systemic Hurdles

Central to Genetix's 2026 strategy is a massive expansion of its manufacturing capabilities. The company plans to double its commercial manufacturing capacity by the middle of this year, leaning on established contract development and manufacturing organizations (CDMOs) Minaris, Lonza, and MilliporeSigma. This move is critical to overcoming one of the biggest bottlenecks in the gene therapy sector: the complex, individualized, and time-sensitive nature of producing autologous therapies, where a patient's own cells are harvested, modified, and re-infused.

Beyond the lab, the challenge of patient access remains formidable. Genetix reports that its therapies have "meaningful access for >90% of eligible patients with commercial or Medicaid coverage" and that its network of Qualified Treatment Centers (QTCs) has grown to 70 sites nationwide. However, access in the world of gene therapy is a multi-faceted issue.

The list price for LYFGENIA is $3.1 million per treatment, a figure that presents a substantial challenge for payers, even with outcomes-based agreements. Furthermore, the treatment process itself is an arduous journey for patients and their families, requiring lengthy hospital stays for chemotherapy conditioning, specialized care, and often significant travel to one of the 70 QTCs. For the estimated 66% of the U.S. sickle cell population covered by Medicaid, navigating reimbursement can be particularly complex, though new federal initiatives like the CMS Gene and Cell Therapy Access Model aim to streamline this process.

A Competitive Field and a Double-Edged Sword

While Genetix's patient numbers are growing, it does not operate in a vacuum. The company's claim as the "market leader" is challenged by formidable competition. In late 2023, Vertex Pharmaceuticals and CRISPR Therapeutics received FDA approval for Casgevy, the first-ever CRISPR-based gene-editing therapy, which treats both sickle cell disease and beta-thalassemia. With a list price of $2.2 million, Casgevy presents a significant competitive and pricing pressure in the market.

This intense competition unfolds against a backdrop of complex safety considerations. The transformative potential of these therapies is weighed against serious risks. LYFGENIA’s label carries a stark Boxed WARNING for hematologic malignancy, or blood cancer. During clinical trials, two patients treated with an earlier version of the therapy developed acute myeloid leukemia (AML), and another developed myelodysplastic syndrome (MDS).

As a result, patients who receive LYFGENIA must undergo lifelong monitoring, including blood counts at least every six months for 15 years, to watch for any signs of malignancy. Other severe side effects, largely related to the necessary high-dose chemotherapy that wipes out a patient's bone marrow before the modified cells are infused, include severe mouth sores, low platelet and white blood cell counts, and increased risk of infection. This "double-edged sword"—the promise of a cure versus the peril of the treatment—remains the central narrative for patients considering these advanced medicines.

The Next Generation: Pushing into Pediatric Care

Looking ahead, Genetix is setting its sights on a younger patient population. A key strategic priority for 2026 is advancing the HGB-210 clinical study, which is evaluating LYFGENIA in children with sickle cell disease who are under 12 years old. The trial, which has an estimated primary completion date in late 2025, could pave the way for a regulatory submission to expand the therapy's approval to this younger demographic.

Treating sickle cell disease earlier in life could prevent the decades of cumulative, irreversible organ damage that the condition causes. However, this move will also bring heightened scrutiny from regulators and clinicians. The long-term risks, including the potential for blood cancer and the impact of conditioning chemotherapy on a developing child's body and future fertility, will be paramount considerations. Successfully navigating this expansion will be a critical test for Genetix as it works to solidify its position in the rapidly evolving landscape of genetic medicine.